Citations

Clear

421 citation(s) found for "Short, C".

Occipital nerve block for the short-term preventive treatment of migraine: A randomized, double-blinded, placebo-controlled study
Dilli, Esma, Halker, Rashmi, Vargas, Bert B., Hentz, Joseph G. , Radam, Teresa, Rogers, Robert , Vargas, Bert, Hentz, Joseph, Dodick, David, Dodick, David W.

Mayo Clinic

Cephalalgia | December 12, 2014 | Volume: 35 | Issue: 11 | Pages: 959-968

10.1177/0333102414561872 | PMID 25505035 Get It

Background Occipital nerve (ON) injections with corticosteroids and/or local anesthetics have been employed for the acute and preventive treatment of migraine for decades. However, to date there is no randomized, placebo-controlled evidence to support the use of occipital nerve block (ONB) for the prevention of migraine. Objective The objective of this article is to determine the efficacy of ONB with local anesthetic and corticosteroid for the preventive treatment of migraine. Participants and methods Patients between 18 and 75 years old with ICHD-II-defined episodic (> 1 attack per week) or chronic migraine (modified ICHD-II as patients with > 10 days with consumption of acute medications were permitted into the study) were randomized to receive either 2.5 ml 0.5% bupivacaine plus 0.5 ml (20 mg) methylprednisolone over the ipsilateral (unilateral headache) or bilateral (bilateral headache) ON or 2.75 ml normal saline plus 0.25 ml 1% lidocaine without epinephrine (placebo). Patients completed a one-month headache diary prior to and after the double-blind injection. The primary outcome measure was defined as a 50% or greater reduction in the frequency of days with moderate or severe migraine headache in the four-week post-injection compared to the four-week pre-injection baseline period. Results Thirty-four patients received active and 35 patients received placebo treatment. Because of missing data, the full analysis of 33 patients in the active and 30 patients in the placebo group was analyzed for efficacy. In the active and placebo groups respectively, the mean frequency of at least moderate (mean 9.8 versus 9.5) and severe (3.6 versus 4.3) migraine days and acute medication days (7.9 versus 10.0) were not substantially different at baseline. The percentage of patients with at least a 50% reduction in the frequency of moderate or severe headache days was 30% for both groups (10/30 vs nine of 30, Δ 0.00, 95% CI –0.22 to 0.23). Conclusions Greater ONB does not reduce the frequency of moderate to severe migraine days in patients with episodic or chronic migraine compared to placebo. The study was registered with ClinicalTrial.gov (NCT00915473).
Short Myelitis Lesions in Aquaporin-4-IgG–Positive Neuromyelitis Optica Spectrum Disorders
Flanagan, Eoin P. , Weinshenker, Brian G. , Krecke, Karl N. , Lennon, Vanda A. , Lucchinetti, Claudia F. , McKeon, Andrew , Wingerchuk, Dean M. , Shuster, Elizabeth A., Jiao, Yujuan , Horta, Erika , Pittock, Sean J. , Horta, Erika S, Pittock, S J , Flanagan, E P , Weinshenker, Brian G , McKeon, Andrew

Mayo Clinic

JAMA Neurology | November 10, 2014 | Volume: 72 | Issue: 1 | Pages: 81

10.1001/jamaneurol.2014.2137 | PMID 25384099 Get It

Predictors for Glucose Change in Hypertensive Participants Following Short‐term Treatment with Atenolol or Hydrochlorothiazide
Moore, Mariellen J., Hou, Wei , Hall, Karen , Schmidt, Siegfried , Curry, Robert W., Beitelshees, Amber L. , Chapman, Arlene B. , Schwartz, Gary L. , Bailey, Kent R. , Boerwinkle, Eric , Gums, John G. , Johnson, Julie A. , Beitelshees, Amber L. , Gong, Yan , Chapman, Arlene B. , Turner, Stephen T. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | September 9, 2014 | Volume: 34 | Issue: 11 | Pages: 1132-1140

10.1002/phar.1483 | PMID 25202885 Get It

Study ObjectiveTo develop and validate a predictive model for glucose change and risk for new‐onset impaired fasting glucose in hypertensive participants following treatment with atenolol or hydrochlorothiazide (HCTZ).DesignRandomized multicenter clinical trial.PatientsA total of 735 white or African‐American men and women with uncomplicated hypertension.Measurements and Main ResultsPharmacogenomic Evaluation of Antihypertensive Responses (PEAR) is a randomized clinical trial to assess the genetic and nongenetic predictors of blood pressure response and adverse metabolic effects following treatment with atenolol or HCTZ. To develop and validate predictive models for glucose change, PEAR participants were randomly divided into a derivation cohort of 367 and a validation cohort of 368. Linear and logistic regression modeling were used to build models of drug‐associated glucose change and impaired fasting glucose (IFG), respectively, in the derivation cohorts. These models were then evaluated in the validation cohorts. For glucose change after atenolol or HCTZ treatment, baseline glucose was a significant (p<0.0001) predictor, explaining 13% of the variability in glucose change after atenolol and 12% of the variability in glucose change after HCTZ. Baseline glucose was also the strongest and most consistent predictor (p<0.0001) for development of IFG after atenolol or HCTZ monotherapy. The area under the receiver operating curve was 0.77 for IFG after atenolol and 0.71 after HCTZ treatment, respectively.ConclusionBaseline glucose is the primary predictor of atenolol or HCTZ‐associated glucose increase and development of IFG after treatment with either drug.
O4‐12‐02: SHORT‐TERM MEMORY BINDING IN PRESYMPTOMATIC APOE E4 CARRIERS
Caselli, Richard J. , Locke, Dona E.C. , Parra, Mario A.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2014.04.452 Get It

Prediction of Pica Overall Score by Short Versions of the Test
DiSimoni, Frank G., Keith, Robert L. , Darley, Frederic L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | July 29, 2014 | Volume: 23 | Issue: 3 | Pages: 511-516

10.1044/jshr.2303.511 | PMID 7421154 Get It

Two short versions (SPICAs) of the Porch Index of Communicative Ability (PICA)were developed and investigated, with specific attention to their ability to predict standard PICA overall scores of patients with aphasia. Ninety-three patients were administered three versions of the test in randomized order. Results indicate that SPICAs predict overall scores by standard administration at acceptable confidence levels in approximately one-third of the time required for the administration of the standard PICA.
Allergic Inflammatory Response to Short Ragweed Allergenic Extract in HLA-DQ Transgenic Mice Lacking CD4 Gene
Chapoval, Svetlana P. , Iijima, Koji, Marietta, Eric, Smart, Michele, Chapoval, Andrei I. , Andrews, Amy G., David, Chella S.

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 168 | Issue: 2 | Pages: 890-899

10.4049/jimmunol.168.2.890 | PMID 11777987 Get It

Abstract To investigate the role of HLA-DQ molecules and/or CD4+ T cells in the pathogenesis of allergic asthma, we generated HLA-DQ6 and HLA-DQ8 transgenic mice lacking endogenous class II (Aβnull) and CD4 genes and challenged them intranasally with short ragweed allergenic extract (SRW). We found that DQ6/CD4null mice developed a strong eosinophilic infiltration into the bronchoalveolar lavage and lung tissue, while DQ8/CD4null mice were normal. However, neither cytokines nor eosinophil peroxidase in the bronchoalveolar lavage of DQ6/CD4null mice was found. In addition, the airway reactivity to methacholine was elevated moderately in DQ6/CD4null mice compared with the high response in DQ/CD4+ counterparts and was only partially augmented by CD4+ T cell transfer. The DQ6/CD4null mice showed Th1/Th2-type cytokines and SRW-specific Abs in the immune sera in contrast to a direct Th2 response observed in DQ6/CD4+ mice. The proliferative response of spleen mononuclear cells and peribronchial lymph node cells demonstrated that the response to SRW in DQ6/CD4null mice was mediated by HLA-DQ-restricted CD4−CD8−NK1.1− T cells. FACS analysis of PBMC and spleen mononuclear cells demonstrated an expansion of double-negative (DN) CD4−CD8−TCRαβ+ T cells in SRW-treated DQ6/CD4null mice. These cells produced IL-4, IL-5, IL-13, and IFN-γ when stimulated with immobilized anti-CD3. IL-5 ELISPOT assay revealed that DN T cells were the cellular origin of IL-5 in allergen-challenged DQ6/CD4null mice. Our study shows a role for HLA-DQ-restricted CD4+ and DN T cells in the allergic response.
Short-stem uncemented primary reverse shoulder arthroplasty
Giuseffi, Steven A., Streubel, Philipp N. , Sperling, John W. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

The Bone & Joint Journal | April 1, 2014 | Volume: 96-B | Issue: 4 | Pages: 526-529

10.1302/0301-620x.96b3.32702 | PMID 24692622 Get It

Short uncemented humeral stems can preserve humeral bone stock and facilitate revision surgery but may be prone to malalignment or loosening, especially when used in reverse total shoulder replacement (TSR). We undertook a retrospective review of 44 patients with a mean age of 76 years (59 to 92) who underwent primary reverse TSR with a short uncemented humeral stem. There were 29 females. The indications for joint replacement included cuff tear associated arthropathy (33), avascular necrosis (six), post-traumatic arthritis (two), and inflammatory arthritis (three). At a mean follow-up of 27 months (24 to 40), pain was rated as mild or none in 43 shoulders (97.7%). The mean active elevation improved from 54° (sd 20°) to 142° (sd 25°) and the mean active external rotation from 14° (sd 13°) to 45° (sd 9°). The outcome, as assessed by the modified Neer score, was excellent in 27 (61.3%), satisfactory in 15 (34.1%), and unsatisfactory in two shoulders (4.5%). Stems were well-positioned, without evidence of significant valgus or varus malalignment in 42 TSRs (95.5%). There was no radiological evidence of loosening of the humeral stem in any patient; 13 TSRs (29.5%) had evidence of proximal humeral remodelling and scapular notching was noted in three (6.8%). Cite this article: Bone Joint J 2014;96-B:526–9.
Estimating long‐term multivariate progression from short‐term data
Donohue, Michael , Jacqmin‐Gadda, Hélène , Goff, Mélanie Le , Thomas, Ronald G. , Raman, Rema , Gamst, Anthony, Weiner, Michael W. , Dartigues, Jean‐François , Aisen, Paul , Hsiung, Ging‐Yuek Robin , Preda, Adrian , Jicha, Gregory A. , Ponto, Laura L. Boles , Beckett, Laurel , Jack, Clifford R. , Preda, Adrian , Hsiung, Gink-Yuek , Donohue, Michael C , Jicha, Gregory A

Mayo Clinic

Alzheimer's & Dementia | March 22, 2014 | Volume: 10 | Issue: 5S | Pages: No page available

10.1016/j.jalz.2013.10.003 | PMID 24656849 Get It

AbstractMotivationDiseases that progress slowly are often studied by observing cohorts at different stages of disease for short periods of time. The Alzheimer's Disease Neuroimaging Initiative (ADNI) follows elders with various degrees of cognitive impairment, from normal to impaired. The study includes a rich panel of novel cognitive tests, biomarkers, and brain images collected every 6 months for as long as 6 years. The relative timing of the observations with respect to disease pathology is unknown. We propose a general semiparametric model and iterative estimation procedure to estimate simultaneously the pathological timing and long‐term growth curves. The resulting estimates of long‐term progression are fine‐tuned using cognitive trajectories derived from the long‐term “Personnes Agées Quid” study.ResultsWe demonstrate with simulations that the method can recover long‐term disease trends from short‐term observations. The method also estimates temporal ordering of individuals with respect to disease pathology, providing subject‐specific prognostic estimates of the time until onset of symptoms. When the method is applied to ADNI data, the estimated growth curves are in general agreement with prevailing theories of the Alzheimer's disease cascade. Other data sets with common outcome measures can be combined using the proposed algorithm.AvailabilitySoftware to fit the model and reproduce results with the statistical software R is available as the grace package. ADNI data can be downloaded from the Laboratory of NeuroImaging.
Comparison of EEG Background Frequency Analysis, Psychologic Test Scores, Short Test of Mental Status, and Quantitative SPECT in Dementia
Herkes, Geoffrey , Lagerlund, Terrence D., Kokmen, Emre, Wszołek, Zbigniew K.

Mayo Clinic

Journal of Geriatric Psychiatry and Neurology | March 18, 2014 | Volume: 5 | Issue: 1 | Pages: 22-30

10.1177/002383099200500104 | PMID 1571070 Get It

Fourteen patients who had cognitive dysfunction were studied with quantitative electroencephalography (EEG), singlephoton emission computed tomography (SPECT), and several tests of intellectual and memory function, including the Wechsler Adult Intelligence Scale (WAIS), the Auditory Verbal Learning Test, and the Short Test of Mental Status, to determine whether EEG background frequency content correlates with degree of dementia and with regional uptake of radioisotope on SPECT. The factors from spectral analysis that correlated best with psychometric data were mean frequency in the 1.5– to 20-Hz range and percentage power in the 13- to 20-Hz band (positive correlation) or the 1.5- to 8-Hz band (negative correlation). The WAIS subtest scores that correlated most with the EEG data were performance IQ and perceptual organization. Correlations between percentage power and amplitude ratio in the EEG frequency bands and regional SPECT counts were found, but most were not statistically significant. ( J Geriatr Psychiatry Neurol 1992;5:22–30).
Short Communication: CD4 T Cell Declines Occurring During Suppressive Antiretroviral Therapy Reflect Continued Production of Casp8p41
Neuhaus, Jacqueline, Sainski, Amy M., Strausbauch, Michael, Wettstein, Peter J., Lewin, Sharon R. , Plana, Montserrat, Rizza, Stacey A. , Temesgen, Zelalem , Touloumi, Giota , Freiberg, Matthew S. , Neaton, James D. , Badley, Andrew D. , Group, for the INSIGHT SMART Study, Cummins, Nathan W. , Plana, Montserrat , Group, for the INSIGHT SMART Study, Badley, Andrew D , Nordwall, Jacqueline

Mayo Clinic

AIDS Research and Human Retroviruses | December 18, 2013 | Volume: 30 | Issue: 5 | Pages: 476-479

10.1089/aid.2013.0243 | PMID 24344953 Get It